Updates on the use of bispecific antibodies in MCL & the need for more studies in this space

Updates on the use of bispecific antibodies in MCL & the need for more studies in this spaceПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Developments in the use of bispecific antibodies in myeloma and challenges in this spaceПодробнее

Advice for Treating Patients With MCLПодробнее

Challenges in using CAR-T therapy & BTK inhibitors in patients with R/R MCLПодробнее

Clinical guidance for the use of bispecific antibodies in NHLПодробнее

Bispecific antibodies in lymphoma: an updateПодробнее

Promising agents being explored in R/R MCL: bispecific antibodies and BTK inhibitorsПодробнее

Updates on the use of CAR-T therapy in MCLПодробнее

Advancing MCL treatment: combination therapies and updates from SYMPATICOПодробнее

The Next Phase of Targeted Therapy in MCL and DLBCLПодробнее

What are Bispecific Antibodies?Подробнее

How Bispecific Antibodies WorkПодробнее

How Bispecific Antibodies WorkПодробнее

Bispecific Antibodies in MyelomaПодробнее

Bispecific Antibodies for B-cell Lymphoma Treatment | OncotargetПодробнее

Tycel Phillips, MD, on Glofitamab Research, Progress in Mantle Cell LymphomaПодробнее

Emerging therapies in MCL: the promise of immunotherapiesПодробнее

Advances in the use of bispecific antibodies for the treatment of CLLПодробнее

Safety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma subtypesПодробнее